Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2251 to 2265 of 9039 results

  1. Acalabrutinib with venetoclax for untreated chronic lymphocytic leukaemia [ID6232]

    In development Reference number: GID-TA11230 Expected publication date:  19 August 2026

    Technology appraisal guidance
    In development

  2. Gender Incongruence Services for Children and Young People

    In development Reference number: GID-QS10193 Expected publication date:  18 February 2027

    Quality standard
    In development

  3. Gender incongruence in children and young people

    Topic prioritisation

    NICE guideline
    Topic prioritisation

  4. Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 30 June 2026.

    Technology appraisal guidance
    In consultation

  5. Software with artificial intelligence (AI)-derived algorithms to help interpret electroencephalograms (EEGs) for suspected epilepsy: early-use assessment: draft guidance

    We are listening to your views on this HealthTech guidance. Comments close 30 June 2026.

    In consultation

  6. Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]

    In development Reference number: GID-TA11651 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Brentuximab vedotin in combination for untreated advanced classical Hodgkin lymphoma [ID6437]

    In development Reference number: GID-TA11516 Expected publication date:  06 May 2027

    Technology appraisal guidance
    In development

  8. Baloxavir marboxil granules for treating and preventing influenza in people 3 weeks and over [TSID12432]

    Awaiting development Reference number: GID-TA12479 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]

    In development Reference number: GID-TA11545 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]

    In development Reference number: GID-TA11414 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Teprotumumab for treating thyroid eye disease (deferred appraisal of D1) [ID6756]

    In development Reference number: GID-TA11995 Expected publication date:  08 October 2026

    Technology appraisal guidance
    In development

  12. Efgartigimod for treating chronic inflammatory demyelinating polyneuropathy [ID6409]

    In development Reference number: GID-TA11508 Expected publication date:  18 November 2026

    Technology appraisal guidance
    In development

  13. CaRi-Heart for predicting cardiac risk in adults with suspected coronary artery disease (CAD)

    In development Reference number: GID-HTE10085 Expected publication date:  02 December 2026

    In development

  14. Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]

    In development Reference number: GID-TA11100 Expected publication date:  13 May 2027

    Technology appraisal guidance
    In development

  15. Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

    In development Reference number: GID-TA10575 Expected publication date:  05 August 2026

    Technology appraisal guidance
    In development